Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Frailty assessment in multiple myeloma (MM) is crucial for older adults. Adapting MM therapy for frail patients may improve treatment outcomes and quality of life.
Area Of Science
- Gerontology
- Hematology
- Oncology
Background
- Multiple myeloma (MM) predominantly affects older adults, a demographic with high prevalence of frailty.
- Frailty, a syndrome of decreased physiological reserve and increased vulnerability, negatively impacts treatment outcomes in elderly patients.
- Understanding frailty's role is critical for optimizing care in older MM patients.
Purpose Of The Study
- To review methods for assessing frailty in multiple myeloma patients.
- To analyze treatment outcomes in frail adults with multiple myeloma using existing data.
- To explore the relationship between frailty, quality of life, and patient-reported outcomes in MM therapy.
Main Methods
- Systematic review of tools and strategies for frailty assessment in MM.
- Analysis of clinical trial and real-world data on treatment outcomes in frail MM patients.
- Evaluation of frailty's impact on quality of life and patient-reported outcomes.
Main Results
- Frailty is common in older multiple myeloma patients and associated with poorer outcomes.
- Various tools exist to assess frailty, aiding in risk stratification.
- Evidence suggests frailty impacts quality of life and patient-reported outcomes during MM treatment.
Conclusions
- Frailty assessment is essential for managing older adults with multiple myeloma.
- Tailoring therapy based on frailty status holds promise for improving patient outcomes.
- Frailty-adapted treatment strategies can enhance the quality of life for elderly MM patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Survival Times Are Positively Skewed
Survival times often exhibit positive skewness, unlike the normal distribution assumed...